Sign in
Taking people in United StatesPhase 1

huCART19-IL18-eDHFR CAR T cells for follicular lymphoma that returned or did not respond

Tests huCART19-IL18-eDHFR cells in adults whose follicular lymphoma returned or resisted treatment.

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
huCART19-IL18-eDHFR Cells in Relapsed/Refractory Follicular Lymphoma
Status
Recruiting
Phase
Phase 1
People taking part
6 people, planned
Started
18 May 2026
Expected to end
Nov 2042
Type of study
Interventional, 2 groups
Treatments tested
  • huCART19-IL18-eDHFR cells
  • [18F]Fluoropropyl-Trimethoprim
Record updated
16 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults whose follicular lymphoma came back or did not respond after at least 2 earlier treatments, and whose lymphoma cells carry CD19.

Age
18 years or older
Sex
All sexes can join.
Disease stage
Follicular lymphoma, grades 1-3A, that came back or did not respond after at least 2 prior lines of treatment; it must have progressed within 2 years after the second or later line, with signs of progression within 12 weeks of confirmation.
Earlier treatment
Must have had an anti-CD20 antibody and an alkylating agent or lenalidomide. Cannot have had earlier huCART19 or huCART19-IL18 therapy.
Biomarker or test result
CD19 on the lymphoma cells, shown by flow cytometry or IHC at a CLIA certified laboratory within 6 months.

Main reasons for not taking part

  • Active hepatitis B or hepatitis C infection
  • Any active infection that is not controlled
  • Active CNS involvement by the lymphoma
  • Known allergy to trimethoprim or Bactrim (TMP-SMX)
  • Pregnant or breastfeeding

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Signed informed consent form
  • Male or females age ≥ 18 years
  • Diagnosis of follicular lymphoma, grades 1-3A
  • Relapsed or refractory disease after at least 2 prior lines of systemic therapy as follows:; Prior therapy must include an anti-CD20 monoclonal or bispecific antibody and an alkylating agent or lenalidomide; Must have progressed within 2 years after second or higher line of therapy
  • Documentation of CD19 expression on malignant cells by flow cytometry/IHC from a CLIA certified laboratory. Results must be within 6 months of physician-investigator confirmation of eligibility and after any intervening CD19 directed therapy since expression confirmed
  • Patients with relapsed disease after prior allogeneic SCT must meet the following criteria:; Have no active GVHD and require no immunosuppression; Are more than 6 months from transplant at the time of physician-investigator confirmation of eligibility
  • Evidence of progressive disease within 12 weeks of physician-investigator confirmation of eligibility
  • ECOG Performance Status that is either 0 or 1
  • Adequate organ function defined as:; Serum creatinine ≤ 1.5x ULN or estimated creatinine clearance ≥ 35 mL/min and not on dialysis; ALT/AST ≤ 3 x ULN; Direct bilirubin ≤ 2.0 mg/dl; for patients with Gilbert's syndrome direct bilirubin must be ≤ 3.0 mg/dl; Left Ventricular Ejection Fraction (LVEF) ≥ 40% confirmed by ECHO/MUGA; Must have minimum level of pulmonary reserve defined as ≤ Grade 1 dyspnea and pulse oxygen > 92% on room air

Who cannot take part

  • Active acute or chronic GVHD requiring systemic therapy
  • Dependence on systemic steroids or immunosuppressant medications. For additional details regarding use of steroid and immunosuppressant medications, please see Section 5.3
  • Receipt of prior huCART19 or huCART19-IL18 therapy
  • Active treatment with trimethoprim, methotrexate, or other antifolate chemotherapy, or anticipated use of these drugs during the active treatment phase of the study. For additional details regarding these restrictions, please see Section 5.3
  • Prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen
  • Active hepatitis B or hepatitis C infection
  • Any active, uncontrolled infection
  • Class III/IV cardiovascular disability according to the New York Heart Association Classification (See Appendix 5)
  • Clinically apparent arrhythmia or arrhythmias that are not stable on medical management within two weeks of physician-investigator confirmation of eligibility
  • Active CNS involvement. Patients with a history of CNS involvement that was successfully treated are eligible. A CNS evaluation is only required for eligibility if a subject is experiencing signs/symptoms of CNS involvement
  • Known allergy to trimethoprim or Bactrim (TMP-SMX)
  • Active autoimmune disease requiring systemic immunosuppressive treatment equivalent to ≥ 10mg daily of prednisone. Patients with autoimmune neurologic diseases (such as MS) will be excluded
  • History of allergy or hypersensitivity to study product excipients (human serum albumin, DMSO, and Dextran 40)
  • Severe, active co-morbidity that, in the opinion of the physician-investigator, would preclude participation in this study
  • Pregnant or nursing (lactating) patients. Participants of reproductive potential must agree to use acceptable birth control methods, as described in Protocol Section 4.3

Where in United States

  • University of PennsylvaniaPhiladelphia, United StatesContact: Abramson Cancer Center Clinical Trials ServiceTaking people

About the trial

What the trial wants to find out

This is a phase 1, open-label study to evaluate the feasibility, safety and preliminary efficacy of huCART19-IL18-eDHFR cells administered in patients with relapsed or refractory follicular lymphoma. This study will be initiated as a single arm study (Treatment Arm A), which will evaluate the use of huCART19-IL18-eDHFR cells without prior lymphodepletion. In this Treatment Arm A, all subjects will receive a single flat dose of 7x10[6] huCART19-IL18-eDHFR cells (Dose Level 1; DL1). Additional treatment arms may also be introduced in the future, via subsequent amendment(s).

Read full original descriptionShow less

Co-expression of eDHFR within huCART19-IL18 cells will allow the trafficking of the transduced CAR T cells to be visualized by PET/CT imaging using an investigational radiolabeled imaging agent [18F]Fluoropropyl-Trimethoprim (also known as [18F]FP-TMP). The feasibility of using [18F]FP-TMP PET/CT imaging to detect and measure the eDHFR-expressing CAR T cells will be investigated, as well as its ability to provide insight into CAR T cell pharmacokinetics, biodistribution, and persistence.

The 2 groups in the trial

  • Arm A - DL1Treatment being tested

    IV administration of a single flat dose of 7x10\[6\] huCART19-IL18-eDHFR cells. \[18F\]FP-TMP PET/CT scan.

    Treatment: huCART19-IL18-eDHFR cells and [18F]Fluoropropyl-Trimethoprim

  • Arm A - DL-1Treatment being tested

    IV administration of a single flat dose of 3x10\[6\] huCART19-IL18-eDHFR cells. \[18F\]FP-TMP PET/CT scan.

    Treatment: huCART19-IL18-eDHFR cells and [18F]Fluoropropyl-Trimethoprim

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Phase 1 Study of huCART19-IL18-eDHFR Cells in Patients With Relapsed or Refractory Follicular Lymphoma
Plain-language title
huCART19-IL18-eDHFR CAR T cells for follicular lymphoma that returned or did not respondGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
16 September 2026